Laurie Burlingame

Laurie’s clients include pharmaceutical, medical device, diagnostics, biological materials and tools, and technology companies. She also represents life sciences–focused venture capital firms in connection with their portfolio company investments.

Laurie is active in several nonprofit organizations, serving on the boards of directors for Sitters for Scholars and Families for Depression Awareness. In addition, she is a mentor and speaker for various university and incubator programs and maintains membership in local technology and medical associations.

Private Company Financings

• A company focused on longevity in its Series A and Series B Preferred Stock financings that raised more than $2 billion*
• A company focused on severe immune-mediated diseases in its Series A preferred stock and Series A preferred stock extension financings that raised more than $125 million*
• A company focused on transforming oncology clinical trials in its Series Seed preferred stock financing that raised $23 million*
• A company focused on neuroscience in its Series A, Series A-1, and Series B financings that raised more than $125 million*
• A company focused on complement biology in its Series A and Series B financings that raised more than $100 million*

M&A Transactions

• A venture capital fund in its up to $110 million collaboration with the Cystic Fibrosis Foundation to accelerate the development of genetic therapies for cystic fibrosis*
• A private company focused on neuroscience in its collaboration with an option to be acquired by a pharma company*
• A private company focused on complement biology in its collaboration with an option to be acquired by a pharma company*
• A private company in connection with its spinout and acquisition by a pharma company*
• A private company focused on gene therapy in ophthalmology in connection with its spinout and acquisition by a pharma company*
• An Italian company in its sale of shares to a private US company*
• A private company in the imaging space in connection with its spinout and acquisition by a medical device company*

 Public Offerings

• Initial public offering and follow-on offerings for a company focused on targeting the precursors of growth factors*
• Initial public offering and follow-on offerings for a company focused on developing treatments based on the microbiome*
• Initial public offering and follow-on offerings for a company focused on developing treatments for NASH and long COVID*
• Initial public offering for a company focused on the development of treatments for the central nervous system*
• An operating company in the ophthalmology space in connection with its de-SPAC transaction*
• A SPAC in its de-SPAC transaction with a next-generation radiopharmaceuticals company*
• A SPAC in its de-SPAC transaction with a regenerative medicine company*

* Represents transaction completed prior to joining Morgan Lewis